Brind.

AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.

Steady: 1 in the last 7 days Updated yesterday

The latest in this situation

  1. The partnership agreement between Merck and AstraZeneca was amended.

How it started

4 reports, 2 independent, last reported Sun 00:00. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.

Who's involved

What this event is mainly about
Daiichi Sankyo (United Kingdom)AstraZenecaMerck

How it developed

Newest first. Tap a step to see who reported it.
  1. The partnership agreement between Merck and AstraZeneca was amended.1 source
  2. The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.Sub-event
  3. AstraZeneca partnered with Daiichi Sankyo on Enhertu and secured a profit-sharing deal with Merck for Lynparza.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • themarketsdaily.com
  • ZacksAstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca‘s total
  • ZacksHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings? Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is on diabetes an
  • Unknown outlet